Uses Small Drug-Like Molecules to Prevent Cancer Cell Proliferation
This breakthrough approach to treating cancer is efficacious and has limited side effects. Cancer is a leading cause of death in the United States, accounting for one in four deaths annually, according to the American Cancer Society. An estimated 595,600 Americans will die of cancer-related causes in 2016, and predictions for the future continue to rise. Existing treatments often suffer from a lack of efficacy or lead to debilitating side effects for the patient. Researchers at the University of Florida have developed a distinct therapy to specifically target cancerous cell proliferation and halt the growth of tumors and the spread of cancer. This breakthrough treatment also has minimal side effects, making it a desirable treatment for both the patient and health practitioner.
Application
A therapeutic cancer treatment that inhibits the proliferation of cancer
Advantages
- Capable of preventing and treating cancer and other cell proliferation diseases, offering a therapy that is effective at a lower concentrations
- Decreases cancerous cell proliferation, inhibiting the spread of cancer to other sites and improving the probability of life expectancy
- Minimal side effects, improving patient quality of life and providing a significant market advantage
Technology
This technology is a specially designed therapeutic that treats and prevents cell proliferation diseases such as cancer. Small drug-like molecules are used to bind the dichloroacetate (DCA) binding pocket of pyruvate dehydrogenase kinase isoform 2 (PDK2) and inhibit cancer cell proliferation. A patient suffering from or susceptible to a PDK2 mediated disorder or disease is administered a therapeutically effective amount of a compound that activates PDK2 activity, thereby receiving treatment.
Brochure
